menu
    • menu
    [{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Dalmore Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Dalmore Group","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Dalmore Group"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Undisclosed"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Validcare","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Algernon NeuroScience","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Algernon NeuroScience"}]

    Find Clinical Drug Pipeline Developments & Deals by Algernon NeuroScience

    Menu

    Algernon NeuroScience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Algernon NeuroScience

                            Canada arrow
                            COMPAMED
                            Not Confirmed

                            Algernon NeuroScience

                            Canada arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Validcare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Algernon Appoints Validcare as CRO for DMT Stroke Trial, $170K Equity Investment

                            Details : The partnership aims to advance the clinical development of company's mid-stage product AP-188 (dimethyltryptamine). It is being evaluated for stroke and traumatic brain injury.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 05, 2025

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Validcare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Algernon NeuroScience

                            Canada arrow
                            COMPAMED
                            Not Confirmed

                            Algernon NeuroScience

                            Canada arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

                            Details : AP-188 (N,N-dimethyltryptamine) is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 08, 2023

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Algernon NeuroScience

                            Canada arrow
                            COMPAMED
                            Not Confirmed

                            Algernon NeuroScience

                            Canada arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Dalmore Group

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $1...

                            Details : The capital raised will be used for research, development, and program management costs related to the completion of the Phase 1 DMT (N, N-dimethyltryptamine) study currently underway as well as Phase 2a stroke and traumatic brain injury (TBI) studies.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 03, 2023

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Dalmore Group

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth